NorthStrive Biosciences plans FACS study for EL-22 probiotic candidate
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
NorthStrive Biosciences to Advance EL-22 Manufacturing Characterization with Quantitative FACS Analysis of Latent Myostatin Antigen Expression
July 10, 2026 7:30 AM EDTIndependent flow cytometry (FACS) study will quantify latent myostatin antigen expression on NorthStrive-manufactured Lactobacillus casei and establish comparability against EL-22 material previously manufactured by MOA Life Plus Co. Ltd.
Work is intended to strengthen EL-22 product identity and manufacturing consistency as NorthStrive advances a differentiated engineered probiotic designed to help preserve muscle during weight loss, including with GLP-1 receptor agonists
NEWPORT BEACH, Calif., July 10, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences Inc. (NorthStrive Biosciences), a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB) (PMGC or the Company), today announced plans to initiate an... More
